title: Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks.
abstract: The study of two major risk factors in the development of hepatocellular carcinoma, namely persistent hepatitis virus infection and exposure to dietary aflatoxins, has been hampered by lack of an experimental system. To this end we have used a Pekin duck model to examine the effect of congenital duck hepatitis B virus (DHBV) infection and aflatoxin B1 (AFB1) exposure in the induction and development of liver cancer. AFB1 was administered to DHBV infected or noninfected ducks at two doses (0.08 and 0.02 mg/kg) by i.p. injection once a week from the third month posthatch until they were sacrificed (2.3 years later). Two control groups of ducks not treated with AFB1 (one of which was infected with DHBV) were observed for the same period. Each experimental group included 13-16 ducks. Higher mortality was observed in ducks infected with DHBV and treated with AFB1 compared to noninfected ducks treated with AFB1 and other control ducks. In the groups of noninfected ducks treated with high and low doses of AFB1, liver tumors developed in 3 of 10 and 2 of 10 ducks; in infected ducks treated with the high dose 3 of 6 liver tumors were observed and none in the low dose of AFB1. No liver tumors were observed in the two control groups. Ducks infected with DHBV and treated with AFB1 showed more pronounced periportal inflammatory changes, fibrosis, and focal necrosis compared to other groups. All DHBV carrier ducks showed persistent viremia throughout the observation period. An increase of viral DNA titers in livers and sera of AFB1 treated animals compared to infected controls was frequently observed. No DHBV DNA integration into the host genome was observed, although in one hepatocellular carcinoma from an AFB1 treated duck, an accumulation of viral multimer DNA forms was detected. The metabolism of AFB1 in infected and noninfected duck liver was also examined. The study on the role of DHBV infection and AFB1 in the etiopathogenesis of liver tumors may help to clarify some of the basic mechanisms of carcinogenesis.
authors.affiliation: INSERM Unité U 271, International Agency for Research on Cancer, Lyon, France.
authors.forename: L
authors.initials: L
authors.lastname: Cova
authors.forename: C P
authors.initials: CP
authors.lastname: Wild
authors.forename: R
authors.initials: R
authors.lastname: Mehrotra
authors.forename: V
authors.initials: V
authors.lastname: Turusov
authors.forename: T
authors.initials: T
authors.lastname: Shirai
authors.forename: V
authors.initials: V
authors.lastname: Lambert
authors.forename: C
authors.initials: C
authors.lastname: Jacquet
authors.forename: L
authors.initials: L
authors.lastname: Tomatis
authors.forename: C
authors.initials: C
authors.lastname: Trépo
authors.forename: R
authors.initials: R
authors.lastname: Montesano
mesh_terms: D016604:Aflatoxin B1; D000348:Aflatoxins / Q000378:metabolism / Q000633:toxicity*; D000818:Animals; D004247:DNA / Q000378:metabolism; D004249:DNA Damage; D004279:DNA, Viral / Q000032:analysis; D004372:Ducks; D015611:Hepatitis B Virus, Duck; D006524:Hepatitis, Viral, Animal / Q000150:complications* / Q000382:microbiology; D008099:Liver / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000473:pathology; D008113:Liver Neoplasms / Q000209:etiology* / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000209:etiology* / Q000473:pathology; D015183:Restriction Mapping; D016019:Survival Analysis
chemical_list: D000348:Aflatoxins; D004279:DNA, Viral; D004247:DNA; D016604:Aflatoxin B1